Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI atai Life Sciences	$2.78 +0.9%	$2.01	$1.03 ▼ $2.96	$550.93M	1.44	2.01 million shs	4.12 million shs
CRBU Caribou Biosciences	$1.36 -0.7%	$1.07	$0.66 ▼ $3.00	$127.42M	2.48	1.33 million shs	746,493 shs
TYRA Tyra Biosciences	$10.00 -0.5%	$9.87	$6.42 ▼ $29.60	$533.55M	1.07	286,105 shs	209,584 shs
ZVRA Zevra Therapeutics	$9.79 +4.0%	$8.57	$4.20 ▼ $10.03	$514.53M	1.97	685,187 shs	1.18 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI atai Life Sciences	+1.48%	+25.00%	+10.44%	+109.13%	+111.54%
CRBU Caribou Biosciences	+9.60%	-3.52%	+40.53%	+74.52%	-14.38%
TYRA Tyra Biosciences	+3.40%	+4.36%	+4.69%	+21.08%	-39.82%
ZVRA Zevra Therapeutics	+5.14%	+0.86%	+8.66%	+26.65%	+115.83%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATAI atai Life Sciences	3.1375 of 5 stars	3.7	3.0	3.0	1.7	0.6
CRBU Caribou Biosciences	2.3343 of 5 stars	3.5	1.0	2.7	1.7	0.6
TYRA Tyra Biosciences	1.8257 of 5 stars	3.5	0.0	1.6	3.3	0.0
ZVRA Zevra Therapeutics	2.4119 of 5 stars	3.6	3.0	2.5	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI atai Life Sciences	3.33	Buy	$9.00	224.32% Upside
CRBU Caribou Biosciences	3.00	Buy	$8.50	525.00% Upside
TYRA Tyra Biosciences	3.00	Buy	$30.83	208.49% Upside
ZVRA Zevra Therapeutics	3.11	Buy	$23.14	136.51% Upside

Current Analyst Ratings Breakdown

Latest CRBU, ATAI, ZVRA, and TYRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	ATAI atai Life Sciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $12.00
7/2/2025	ZVRA Zevra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$26.00
7/1/2025	TYRA Tyra Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/21/2025	TYRA Tyra Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$33.00
5/20/2025	ATAI atai Life Sciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$5.00
5/20/2025	ATAI atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/14/2025	ZVRA Zevra Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/14/2025	ZVRA Zevra Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$25.00 ➝ $25.00
5/13/2025	ATAI atai Life Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	CRBU Caribou Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $3.00

(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI atai Life Sciences	$310K	1,793.37	N/A	N/A	$0.69 per share	4.02
CRBU Caribou Biosciences	$9.99M	12.66	N/A	N/A	$2.79 per share	0.49
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	$6.78 per share	N/A
ZVRA Zevra Therapeutics	$23.61M	22.66	N/A	N/A	$0.74 per share	13.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI atai Life Sciences	-$149.27M	-$0.91	N/A	N/A	N/A	N/A	-102.10%	-77.55%	8/12/2025 (Estimated)
CRBU Caribou Biosciences	-$149.10M	-$1.62	N/A	N/A	N/A	-1,490.84%	-55.70%	-45.35%	8/5/2025 (Estimated)
TYRA Tyra Biosciences	-$86.48M	-$1.63	N/A	N/A	N/A	N/A	-26.90%	-25.54%	8/6/2025 (Estimated)
ZVRA Zevra Therapeutics	-$105.51M	-$1.90	N/A	48.93	N/A	-226.78%	-201.05%	-53.55%	8/12/2025 (Estimated)

Latest CRBU, ATAI, ZVRA, and TYRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ATAI atai Life Sciences	-$0.19	-$0.15	+$0.04	-$0.15	N/A	$1.56 million
5/13/2025	Q1 2025	ZVRA Zevra Therapeutics	-$0.21	-$0.06	+$0.15	-$0.06	$16.96 million	$20.40 million
5/8/2025	Q1 2025	CRBU Caribou Biosciences	-$0.43	-$0.43	N/A	-$0.43	$1.48 million	$2.35 million
5/8/2025	Q1 2025	TYRA Tyra Biosciences	-$0.49	-$0.47	+$0.02	-$0.47	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI atai Life Sciences	N/A	N/A	N/A	N/A	N/A
CRBU Caribou Biosciences	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	N/A
ZVRA Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI atai Life Sciences	0.08	4.07	4.07
CRBU Caribou Biosciences	N/A	7.63	7.63
TYRA Tyra Biosciences	N/A	22.78	22.78
ZVRA Zevra Therapeutics	1.46	3.02	2.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI atai Life Sciences	28.41%
CRBU Caribou Biosciences	77.51%
TYRA Tyra Biosciences	84.14%
ZVRA Zevra Therapeutics	35.03%

Insider Ownership

Company	Insider Ownership
ATAI atai Life Sciences	26.80%
CRBU Caribou Biosciences	8.28%
TYRA Tyra Biosciences	15.20%
ZVRA Zevra Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI atai Life Sciences	80	200.34 million	146.65 million	Optionable
CRBU Caribou Biosciences	100	93.00 million	85.30 million	Optionable
TYRA Tyra Biosciences	20	53.09 million	45.02 million	Optionable
ZVRA Zevra Therapeutics	20	54.68 million	53.37 million	Optionable

CRBU, ATAI, ZVRA, and TYRA Headlines

Recent News About These Companies

Zevra Therapeutics (NASDAQ:ZVRA) Stock Price Up 5.9% - Still a Buy?

July 3 at 12:48 PM | marketbeat.com

Zevra Therapeutics (ZVRA) Moves 5.1% Higher: Will This Strength Last?

July 3 at 9:21 AM | zacks.com

Zevra Therapeutics (NASDAQ:ZVRA) Coverage Initiated at HC Wainwright

July 2 at 8:44 AM | marketbeat.com

Brokerages Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Target Price at $22.29

June 23, 2025 | americanbankingnews.com

Carret Asset Management LLC Buys Shares of 36,140 Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

June 21, 2025 | marketbeat.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of "Buy" by Analysts

June 20, 2025 | marketbeat.com

Cantor Fitzgerald Predicts ZVRA FY2026 Earnings

June 11, 2025 | marketbeat.com

Bank of America Corp DE Increases Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

June 9, 2025 | marketbeat.com

Nuveen Asset Management LLC Reduces Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

June 5, 2025 | marketbeat.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Purchased by Millennium Management LLC

June 3, 2025 | marketbeat.com

Zevra Therapeutics: Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

May 31, 2025 | finanznachrichten.de

Zevra Therapeutics Stockholders Re-Elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to Board of Directors Amid Commitment to Growth Strategy

May 31, 2025 | nasdaq.com

Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

May 29, 2025 | globenewswire.com

Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PT

May 27, 2025 | insidermonkey.com

All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees

May 21, 2025 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Flora Growth (FLGC), Cardinal Health (CAH) and Zevra Therapeutics (ZVRA)

May 16, 2025 | theglobeandmail.com

With 49% stake, Zevra Therapeutics, Inc. (NASDAQ:ZVRA) seems to have captured institutional investors' interest

May 15, 2025 | finance.yahoo.com

Zevra Reports First Quarter 2025 Financial Results and Corporate Update

May 13, 2025 | taiwannews.com.twT

Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript

May 13, 2025 | seekingalpha.com

Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates

May 13, 2025 | zacks.com

Zevra Therapeutics, Inc. Q1 2025 Earnings Preview

May 12, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBU, ATAI, ZVRA, and TYRA Company Descriptions

atai Life Sciences NASDAQ:ATAI

$2.78 +0.03 (+0.91%)

Closing price 03:59 PM Eastern

Extended Trading

$2.76 -0.01 (-0.36%)

As of 04:55 PM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Caribou Biosciences NASDAQ:CRBU

$1.36 -0.01 (-0.73%)

Closing price 03:22 PM Eastern

Extended Trading

$1.36 0.00 (0.00%)

As of 04:27 PM Eastern

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Tyra Biosciences NASDAQ:TYRA

$9.99 -0.06 (-0.55%)

Closing price 03:21 PM Eastern

Extended Trading

$9.99 0.00 (0.00%)

As of 04:54 PM Eastern

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Zevra Therapeutics NASDAQ:ZVRA

$9.78 +0.38 (+3.99%)

Closing price 03:52 PM Eastern

Extended Trading

$9.54 -0.24 (-2.45%)

As of 04:48 PM Eastern

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time